Bronchiectasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major bronchiectasis markets reached a value of US$ 438.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 731.5 Million by 2034, exhibiting a growth rate (CAGR) of 4.76% during 2024-2034.
The bronchiectasis market has been comprehensively analyzed in IMARC's new report titled "Bronchiectasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchiectasis refers to a chronic respiratory disorder characterized by the permanent enlargement and damage of the airways in the lungs. In this condition, the bronchi (the larger airways in the lungs) become widened, thickened, and less elastic, leading to the accumulation of mucus and impaired clearance of bacteria and other irritants from the airways. Some of the common symptoms associated with the ailment include chronic cough, which often produces large amounts of thick mucus, recurrent respiratory infections, wheezing, shortness of breath, fatigue, chest discomfort or pain, etc. The diagnosis of bronchiectasis typically involves a combination of medical history evaluation, physical examination, imaging tests, and lung function assessments. The doctor will inquire about disease symptoms, previous respiratory infections, and any underlying conditions. Various imaging procedures, such as high-resolution computed tomography (HRCT) scan, provide detailed images of the airways, enabling the identification of bronchiectasis and its extent. Several lung function tests, including spirometry and lung volume measurements, help to assess lung function and determine any associated respiratory impairments. In some instances, genetic testing may be performed to investigate underlying genetic causes, particularly in suspected cases of cystic fibrosis-related bronchiectasis.
The rising cases of repeated or severe respiratory infections, such as pneumonia, whooping cough, tuberculosis, etc., which cause inflammation and damage to the airway walls, are primarily driving the bronchiectasis market. In addition to this, the increasing prevalence of certain autoimmune conditions like rheumatoid arthritis, cystic fibrosis, immunodeficiency disorders, etc., that increase the risk of bronchiectasis, is also creating a positive outlook for the market. Moreover, the widespread adoption of numerous mucolytic medications, such as mannitol and hypertonic saline, since they can help in thinning the mucus, thereby rendering it easier to clear from the airways, is further augmenting the market growth. Additionally, several key players are making extensive investments in R&D activities to investigate the potential of various biologics, including monoclonal antibodies, in reducing airway inflammation and preventing exacerbations. This, in turn, is also acting as another significant growth-inducing factor. Furthermore, the escalating demand for oscillatory positive expiratory pressure devices (OPEP), which are handheld devices that help to create vibrations in the airways during exhalation and facilitate mucus clearance, is expected to drive the bronchiectasis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the bronchiectasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchiectasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchiectasis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bronchiectasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bronchiectasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bronchiectasis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bronchiectasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bronchiectasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bronchiectasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bronchiectasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchiectasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchiectasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bronchiectasis across the seven major markets?
What is the size of the bronchiectasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bronchiectasis?
What will be the growth rate of patients across the seven major markets?
Bronchiectasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bronchiectasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchiectasis market?
What are the key regulatory events related to the bronchiectasis market?
What is the structure of clinical trial landscape by status related to the bronchiectasis market?
What is the structure of clinical trial landscape by phase related to the bronchiectasis market?
What is the structure of clinical trial landscape by route of administration related to the bronchiectasis market?
The bronchiectasis market has been comprehensively analyzed in IMARC's new report titled "Bronchiectasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchiectasis refers to a chronic respiratory disorder characterized by the permanent enlargement and damage of the airways in the lungs. In this condition, the bronchi (the larger airways in the lungs) become widened, thickened, and less elastic, leading to the accumulation of mucus and impaired clearance of bacteria and other irritants from the airways. Some of the common symptoms associated with the ailment include chronic cough, which often produces large amounts of thick mucus, recurrent respiratory infections, wheezing, shortness of breath, fatigue, chest discomfort or pain, etc. The diagnosis of bronchiectasis typically involves a combination of medical history evaluation, physical examination, imaging tests, and lung function assessments. The doctor will inquire about disease symptoms, previous respiratory infections, and any underlying conditions. Various imaging procedures, such as high-resolution computed tomography (HRCT) scan, provide detailed images of the airways, enabling the identification of bronchiectasis and its extent. Several lung function tests, including spirometry and lung volume measurements, help to assess lung function and determine any associated respiratory impairments. In some instances, genetic testing may be performed to investigate underlying genetic causes, particularly in suspected cases of cystic fibrosis-related bronchiectasis.
The rising cases of repeated or severe respiratory infections, such as pneumonia, whooping cough, tuberculosis, etc., which cause inflammation and damage to the airway walls, are primarily driving the bronchiectasis market. In addition to this, the increasing prevalence of certain autoimmune conditions like rheumatoid arthritis, cystic fibrosis, immunodeficiency disorders, etc., that increase the risk of bronchiectasis, is also creating a positive outlook for the market. Moreover, the widespread adoption of numerous mucolytic medications, such as mannitol and hypertonic saline, since they can help in thinning the mucus, thereby rendering it easier to clear from the airways, is further augmenting the market growth. Additionally, several key players are making extensive investments in R&D activities to investigate the potential of various biologics, including monoclonal antibodies, in reducing airway inflammation and preventing exacerbations. This, in turn, is also acting as another significant growth-inducing factor. Furthermore, the escalating demand for oscillatory positive expiratory pressure devices (OPEP), which are handheld devices that help to create vibrations in the airways during exhalation and facilitate mucus clearance, is expected to drive the bronchiectasis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the bronchiectasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchiectasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchiectasis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bronchiectasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bronchiectasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bronchiectasis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bronchiectasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bronchiectasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bronchiectasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bronchiectasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchiectasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchiectasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bronchiectasis across the seven major markets?
What is the size of the bronchiectasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bronchiectasis?
What will be the growth rate of patients across the seven major markets?
Bronchiectasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bronchiectasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchiectasis market?
What are the key regulatory events related to the bronchiectasis market?
What is the structure of clinical trial landscape by status related to the bronchiectasis market?
What is the structure of clinical trial landscape by phase related to the bronchiectasis market?
What is the structure of clinical trial landscape by route of administration related to the bronchiectasis market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BRONCHIECTASIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BRONCHIECTASIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BRONCHIECTASIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BRONCHIECTASIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BRONCHIECTASIS - UNMET NEEDS
10 BRONCHIECTASIS - KEY ENDPOINTS OF TREATMENT
11 BRONCHIECTASIS - MARKETED PRODUCTS
11.1 List of Bronchiectasis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BRONCHIECTASIS - PIPELINE DRUGS
12.1 List of Bronchiectasis Pipeline Drugs Across the Top 7 Markets
12.1.1 ARINA 1 - Renovion
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BI 1291583 - Boehringer Ingelheim
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 S1226 - SolAeroMed
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Brensocatib - AstraZeneca/Insmed
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BI 1323495 - Boehringer Ingelheim
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BRONCHIECTASIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BRONCHIECTASIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BRONCHIECTASIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bronchiectasis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bronchiectasis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bronchiectasis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bronchiectasis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bronchiectasis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bronchiectasis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bronchiectasis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bronchiectasis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bronchiectasis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bronchiectasis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bronchiectasis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bronchiectasis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bronchiectasis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bronchiectasis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bronchiectasis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bronchiectasis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bronchiectasis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bronchiectasis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bronchiectasis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bronchiectasis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bronchiectasis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bronchiectasis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bronchiectasis - Access and Reimbursement Overview
16 BRONCHIECTASIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BRONCHIECTASIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BRONCHIECTASIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BRONCHIECTASIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BRONCHIECTASIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BRONCHIECTASIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BRONCHIECTASIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BRONCHIECTASIS - UNMET NEEDS
10 BRONCHIECTASIS - KEY ENDPOINTS OF TREATMENT
11 BRONCHIECTASIS - MARKETED PRODUCTS
11.1 List of Bronchiectasis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BRONCHIECTASIS - PIPELINE DRUGS
12.1 List of Bronchiectasis Pipeline Drugs Across the Top 7 Markets
12.1.1 ARINA 1 - Renovion
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BI 1291583 - Boehringer Ingelheim
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 S1226 - SolAeroMed
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Brensocatib - AstraZeneca/Insmed
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BI 1323495 - Boehringer Ingelheim
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BRONCHIECTASIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BRONCHIECTASIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BRONCHIECTASIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bronchiectasis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bronchiectasis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bronchiectasis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bronchiectasis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bronchiectasis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bronchiectasis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bronchiectasis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bronchiectasis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bronchiectasis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bronchiectasis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bronchiectasis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bronchiectasis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bronchiectasis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bronchiectasis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bronchiectasis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bronchiectasis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bronchiectasis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bronchiectasis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bronchiectasis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bronchiectasis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bronchiectasis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bronchiectasis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bronchiectasis - Access and Reimbursement Overview
16 BRONCHIECTASIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BRONCHIECTASIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BRONCHIECTASIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
